Skip to main content
Rajendra Mitra

Rajendra Mitra

Ocular pharmacologist

Talent
Gainesville, AlachuaMember since April 5, 2025
PK and PDOcular biodistributionSystemic dosing routesSD-OCTFundus photographyFluorescein angiographyElectroretinography (ERG)Ophthalmic examination and intraocular inflammation gradingAAV gene therapyInner limiting membraneBlood-retinal barrierRPEImmunohistochemistryElectron microscopy
·

Hire this person

Send a job offer directly to this candidate

PK and PDOcular biodistributionSystemic dosing routesSD-OCTFundus photography

About

Ocular pharmacologist with 3+ years at the bench running in vivo ocular pharmacology studies in retinal disease. I perform the dosing, imaging, and tissue collection myself: intravitreal and subretinal administration in rodents, systemic dosing routes, blood sampling, and dissection of retina, RPE, choroid, and optic nerve for molecular, bioanalytical, and histological endpoints. I acquire and analyze retinal structural and functional data firsthand, including SD-OCT, fundus photography and autofluorescence, fluorescein angiography, electroretinography (ERG), and visual behavior assays such as the optomotor response.

I have advanced genetic medicines in the eye across AAV gene therapy, miRNA, and shRNA, with first-author publications showing functional rescue in retinal degeneration models. Industry experience at AGTC and Apellis spans IND-enabling pharmacokinetics, biodistribution and toxicology support, nonhuman primate ocular studies run with CROs, and a completed pre-IND package. I do my best work in the lab, inside a team.

Experience

Independent Consultant at Independent Consultant, Preclinical Ocular Research (2023-11 – Present)

  • Design in vivo ocular pharmacology studies for early-stage ophthalmology companies, including model selection, dosing route, and endpoint strategy, and interpret the resulting datasets into advance or stop recommendations.
  • Rebuilt R&D plans and target validation packages supporting SBIR submissions.

Principal Scientist, Translational Development, Preclinical at Apellis Pharmaceuticals Inc. (2022-07 – 2023-09)

  • Ran in vitro and in vivo pharmacology for complement-directed geographic atrophy programs, carrying targets from nomination through experimental validation and generating the proof-of-concept data used for biomarker selection and program progression.
  • Established and qualified geographic atrophy models and set the in life and terminal endpoints used to compare candidate molecules, so that programs across the portfolio measured the same things the same way.
  • Designed and executed dose range-finding studies and paired in vivo readouts with PK and PD to define exposure and effect before development commitments were made.
  • Selected and managed CROs and external vendors for model development and sample testing, including strategy, protocols, budgets, and timelines.
  • Reviewed assay results and study reports for technical quality and regulatory fit, and presented data to project teams spanning discovery, translational, and development functions.

R&D Manager, Gene Therapy and Translational Research at Applied Genetic Technologies Corporation (AGTC) (2020-04 – 2022-07)

  • Preclinical AAV gene therapy for inherited retinal disease, including the Complement and dual AAV Stargardt program presented at ASGCT 2022.
  • Designed, executed, and interpreted in vivo proof-of-concept studies in mouse and nonhuman primate, including outcome measures, statistical evaluation, and recommendations when results were ambiguous.
  • Owned the experimental readouts used across programs, including retinal imaging (SD-OCT, fundus photography and autofluorescence, fluorescein angiography), functional assessment (ERG, optomotor response), immunohistochemistry, and route of vector administration, and determined which readouts were fit for each question.
  • Supported IND-enabling toxicology, pharmacokinetics, and ocular biodistribution studies for AAV constructs, including ophthalmic examination and intraocular inflammation grading, from protocol design through report review.
  • Co-led the team that completed the pharmacology proof of concept package for a CNS AAV gene therapy pre-IND submission.
  • Trained and mentored three research associates on surgical dosing, imaging, and study conduct, and held the group to data management, archiving, and SOP standards.

Assistant Professor, Research, Department of Ophthalmology at University of North Carolina at Chapel Hill (2017-12 – 2019-11)

  • Built the in vivo imaging and functional testing workflow the group ran on, including SD-OCT, ERG, fundus imaging, and fluorescein angiography in mice, and wrote the high-content confocal protocol the lab adopted.
  • Performed subretinal and intravitreal dosing in mice and the ocular dissection and tissue processing that followed, generating retinal layer-resolved structural and molecular readouts.
  • Achieved functional rescue of retinal degeneration in the P23H knock-in mouse model of autosomal dominant retinitis pigmentosa using rhodopsin genomic loci nanoparticles. Published in Biomaterials, Molecular Therapy, and Gene Therapy.
  • Demonstrated that an autoregenerative glycol chitosan antioxidant reduced pathology in AMD models. Published in ACS Nano and protected by international patent WO 2018/152283 A1.
  • Ran delivery programs across oligonucleotides, shRNA, miRNA, cDNA, genomic DNA, oligopeptides, and small molecules in retinal disease models and ex vivo retinal culture, studying how ocular barriers including the inner limiting membrane, blood-retinal barrier, and RPE shape distribution and cell type-specific uptake. Stability, solubility, pH, and nuclease work informed formulation and dose selection.
  • Supervised eleven trainees and authored the group SOPs and protocols.

Postdoctoral Research Associate, Department of Ophthalmology at University of North Carolina at Chapel Hill (2014-12 – 2017-11)

Postdoctoral Research Associate, Department of Cell Biology at University of Oklahoma Health Sciences Center (2010-06 – 2014-12)

  • Developed and tested a polymer-based nanoparticle platform delivering miR-200b to suppress VEGF receptor expression and angiogenesis in the Akita mouse model of diabetic retinopathy. Published in Journal of Controlled Release.
  • Showed photoreceptor protection with yttrium oxide nanoparticles in a light damage model of retinal degeneration. Published in Free Radical Biology and Medicine.
  • Characterized several transgenic mouse models of human ocular disease and performed electron microscopy sample preparation from mouse eyes.

Postdoctoral Research Associate at University of Central Florida (2009-06 – 2010-05)

Built multifunctional nanoparticle formulations combining a Stat3 inhibitor with iron oxide nanoparticles and quantum dots to track intracellular drug delivery.

Education

Ph.D. in Chemistry – Indian Association for the Cultivation of Science, Jadavpur University, India

M.S. in Chemistry – University of Burdwan, India

B.S. in Chemistry – University of Burdwan, India

Skills

Ocular pharmacologist

Reviews